ArticleBMC research notes2026
Timeliness of switching to second-line antiretroviral therapy following virologic failure in Dar es Salaam, Tanzania.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTimely transition from first-line to second-line antiretroviral therapy (ART) is critical to prevent treatment failure and minimize resistance. The World Health Organization (WHO) recommends switching within 90 days of confirmed virologic failure (VF). This study assessed the timeliness of switching to second-line ART in three HIV care and treatment clinics in Ilala District, Dar es Salaam.
resultsA retrospective cross-sectional study reviewed patient records from 2019 onward. Data were collected using a structured questionnaire in Kobo Toolbox, verified against patient files, and analyzed in SPSS version 29. Of 5456 patients on ART, 213 were on second-line therapy; 121 patients with complete records were included in the analysis. Most participants were female (69.4%), aged 25-34 years (31.4%), married (49.6%), self-employed (38.8%), and living with family (90.9%). Before switching, most patients had at least two viral load tests (94.3%). The most common second-line regimen was Tenofovir + Emtricitabine + Atazanavir/ritonavir (38.8%). Overall, 72.7% of patients were switched within 90 days of confirmed VF, while 27.3% experienced delays. No statistically significant associations were found between timely switching and sociodemographic or clinical factors. Conclusively, more than 25% of patients experienced delayed switching, indicating suboptimal adherence to WHO-recommended timelines in the studied clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.